Developments in the stem cell world are starting to get very interesting.
On Tuesday, General Electric (GE) signed an exclusive license and alliance pact with Geron (GERN) to develop and commercialize cellular assay products derived from human embryonic stem cells for use in drug discovery, development and toxicity screening. Financial terms of the deal weren't disclosed, but investors clearly saw the deal as a major positive for Geron after the shares soared more than 18% on the news.
This is a very big step for stem cell research development and shows that big firms such as GE are eager to get into the business by partnering up with existing stem cell companies, instead of launching their own stem cell divisions. The implications of this move by GE could force other large companies that want to get into stem cell research to look at partnering up with established players in the sector.
Some of the companies that could see new business flow their way include Aastrom Biosciences (ASTM), Life Technologies (LIFE) Osiris Therapeutics (OSIR) and Neuralstem (CUR). Some of these firms are far from profitable or lack a single stem cell based drug or product that is currently on the market.But now is probably not the time for investors to focus on the lack of earnings or a product. Most of the firms that operate in the stem cell space are still very early into the development stage considering that the controversial practice was banned for more than eight years by former President George Bush. Thanks to the Obama administration, that ban on new embryonic stem cell research and federal funding was finally lifted back in March, so now government money is open to flow into the sector. The potential for stem cells is enormous and now that the political climate has changed the future is starting to look even brighter.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV